Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment.
Gur, Ali, Oktayoglu, Pelin · Current pharmaceutical design · 2008 · DOI
Quick Summary
This review examines how ME/CFS and fibromyalgia may both involve problems in the nervous system—specifically in how the brain processes pain, manages stress hormones, and controls automatic body functions. The authors discuss why current treatments are limited and explore new medication approaches that target brain chemicals involved in pain and fatigue.
Why It Matters
This review directly addresses the long-standing question of whether ME/CFS and fibromyalgia share underlying nervous system mechanisms, which could inform more targeted treatment strategies. Understanding CNS involvement in fatigue, pain, and cognitive symptoms could help clinicians recognize and manage these debilitating conditions more effectively.
Observed Findings
Central nervous system dysfunction is implicated in pain, fatigue, and sleep disturbances in both fibromyalgia and ME/CFS
Cognitive impairment (concentration and memory difficulties) and mood disturbance (depression and anxiety) are common in both disorders
Dysfunction of the hypothalamic-pituitary-adrenal axis is a shared feature between the two conditions
Abnormal pain processing and autonomic nervous system dysfunction are present in both fibromyalgia and ME/CFS
Only pregabalin has FDA approval for fibromyalgia; no pharmacological agent has been reliably shown effective for ME/CFS
Inferred Conclusions
Fibromyalgia and ME/CFS likely share common pathophysiological mechanisms involving central nervous system dysfunction rather than being entirely distinct disorders
Selective serotonin-norepinephrine reuptake inhibitors may offer therapeutic advantages over older tricyclic medications by enhancing descending pain pathway modulation with fewer side effects
Future ME/CFS treatment strategies should focus on symptom relief and minimizing impediments to recovery, pending better understanding of the underlying pathophysiology
Remaining Questions
What are the precise mechanisms linking hypothalamic-pituitary-adrenal axis dysfunction to fatigue and cognitive symptoms in ME/CFS?
What This Study Does Not Prove
This review does not establish causation—it synthesizes existing hypotheses about CNS dysfunction without providing new primary data or definitive proof that nervous system abnormalities directly cause ME/CFS symptoms. The proposed shared mechanisms remain speculative and require validation through rigorous mechanistic studies. This review also does not prove that pharmacological treatments targeting these pathways will be effective for ME/CFS patients.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →